1034 related articles for article (PubMed ID: 25052475)
61. Accuracy and prognostic significance of electrocardiographic markers of left ventricular hypertrophy in a general population: findings from the Pressioni Arteriose Monitorate E Loro Associazioni population.
Cuspidi C; Facchetti R; Bombelli M; Sala C; Grassi G; Mancia G
J Hypertens; 2014 Apr; 32(4):921-8. PubMed ID: 24406778
[TBL] [Abstract][Full Text] [Related]
62. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
[TBL] [Abstract][Full Text] [Related]
63. Prognostic Value of Electrocardiographic Left Ventricular Hypertrophy on Cardiovascular Risk in a Non-Hypertensive Community-Based Population.
Tanaka K; Tanaka F; Onoda T; Tanno K; Ohsawa M; Sakata K; Omama S; Ogasawara K; Ishibashi Y; Itai K; Kuribayashi T; Okayama A; Nakamura M;
Am J Hypertens; 2018 Jul; 31(8):895-901. PubMed ID: 29659657
[TBL] [Abstract][Full Text] [Related]
64. Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placement.
Angeli F; Verdecchia P; Angeli E; Poeta F; Sardone M; Bentivoglio M; Prosciutti L; Cocchieri M; Zollino L; Bellomo G; Rondoni F; Garognoli O; Lenti S; Frigerio C; Gattobigio R; Benemio G; Biscottini B; Panciarola R; Buccolieri M; Liberati R; Trottini M; Cipollini F; Gemelli F; Schillaci G; Porcellati C
J Cardiovasc Med (Hagerstown); 2006 Nov; 7(11):812-6. PubMed ID: 17060807
[TBL] [Abstract][Full Text] [Related]
65. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
66. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Olsen MH; Wachtell K; Bella JN; Palmieri V; Gerdts E; Smith G; Nieminen MS; Dahlöf B; Ibsen H; Devereux RB
Am J Hypertens; 2005 Nov; 18(11):1430-6. PubMed ID: 16280277
[TBL] [Abstract][Full Text] [Related]
67. Prognostic value of left ventricular hypertrophy in hypertensive patients: A meta-analysis of electrocardiographic studies.
Zhang H; Hu L; Wei X
J Clin Hypertens (Greenwich); 2020 Feb; 22(2):254-260. PubMed ID: 31955500
[TBL] [Abstract][Full Text] [Related]
68. ECG left ventricular hypertrophy as a risk predictor of sudden cardiac death.
Porthan K; Kenttä T; Niiranen TJ; Nieminen MS; Oikarinen L; Viitasalo M; Hernesniemi J; Jula AM; Salomaa V; Huikuri HV; Albert CM; Tikkanen JT
Int J Cardiol; 2019 Feb; 276():125-129. PubMed ID: 30293667
[TBL] [Abstract][Full Text] [Related]
69. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
[TBL] [Abstract][Full Text] [Related]
70. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.
Wachtell K; Olsen MH; Dahlöf B; Devereux RB; Kjeldsen SE; Nieminen MS; Okin PM; Papademetriou V; Mogensen CE; Borch-Johnsen K; Ibsen H
J Hypertens; 2002 Mar; 20(3):405-12. PubMed ID: 11875307
[TBL] [Abstract][Full Text] [Related]
71. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
72. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point.
Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Julius S; Dahlöf B
J Am Coll Cardiol; 2001 Aug; 38(2):514-20. PubMed ID: 11499746
[TBL] [Abstract][Full Text] [Related]
73. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Kjeldsen SE; Devereux RB; Hille DA; Lyle PA; Dahlöf B; Julius S; Edelman JM; Snapinn SM; de Faire U; Fyhrquist F; Ibsen H; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Blood Press; 2009; 18(6):348-61. PubMed ID: 20001655
[TBL] [Abstract][Full Text] [Related]
74. Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data).
Greve AM; Gerdts E; Boman K; Gohlke-Baerwolf C; Rossebø AB; Hammer-Hansen S; Køber L; Willenheimer R; Wachtell K
Am J Cardiol; 2011 Aug; 108(4):541-7. PubMed ID: 21624542
[TBL] [Abstract][Full Text] [Related]
75. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania.
Lutale JJ; Thordarson H; Gulam-Abbas Z; Vetvik K; Gerdts E
Cardiovasc J Afr; 2008; 19(1):8-14. PubMed ID: 18320079
[TBL] [Abstract][Full Text] [Related]
76. Left ventricular hypertrophy is a predictor of cardiovascular events in elderly hypertensive patients: Hypertension in the Very Elderly Trial.
Antikainen RL; Peters R; Beckett NS; Fagard RH; Wang JG; Rajkumar C; Bulpitt CJ
J Hypertens; 2016 Nov; 34(11):2280-6. PubMed ID: 27552643
[TBL] [Abstract][Full Text] [Related]
77. ECG left ventricular hypertrophy is a stronger risk factor for incident cardiovascular events in women than in men in the general population.
Porthan K; Niiranen TJ; Varis J; Kantola I; Karanko H; Kähönen M; Nieminen MS; Salomaa V; Huikuri HV; Jula AM
J Hypertens; 2015 Jun; 33(6):1284-90. PubMed ID: 25764049
[TBL] [Abstract][Full Text] [Related]
78. Use of Electrocardiography to Predict Future Development of Hypertension in the General Population.
Takase H; Sugiura T; Murai S; Yamashita S; Ohte N; Dohi Y
Medicine (Baltimore); 2016 Apr; 95(17):e3483. PubMed ID: 27124047
[TBL] [Abstract][Full Text] [Related]
79. Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension.
Mahn JJ; Dubey E; Brody A; Welch R; Zalenski R; Flack JM; Ference B; Levy PD
Acad Emerg Med; 2014 Sep; 21(9):996-1002. PubMed ID: 25269580
[TBL] [Abstract][Full Text] [Related]
80. Distinct role of electrocardiographic criteria in echocardiographic diagnosis of left ventricular hypertrophy according to age, in the general population: the Ikaria Study.
Tsiachris D; Chrysohoou C; Oikonomou E; Lazaros G; Dimitriadis K; Maragiannis D; Roussos D; Andreou I; Tsantilas A; Christoforatou E; Pitsavos C; Panagiotakos D; Stefanadis C
J Hypertens; 2011 Aug; 29(8):1624-32. PubMed ID: 21610511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
